Each point was worked out with the data available that day. Scale 0-10: 5 is the index average and 10 is the cap (+3 standard deviations), not perfection. The vertical axis zooms to fit this company, so two charts are not comparable by eye.
Market and Valuation
Price & Market
Prev Close Price:$553.15
Open:$558.44
Day's Low:$529.15
Day's High:$561.96
Bid / Ask:-
Market Cap:134.53B
Enterprise Value:134.33B
52-Week Range
52-Week Low:$403.16
52-Week High:$568.67
Current position in 52-week range
52w Low-52w High
50-Day Avg:$523.32
200-Day Avg:$479.79
Volume
Volume Today:2,372,462
Avg Volume (3m):1,222,703
Avg Volume (10d):1,641,830
52-Week Change:+31.18%
vs S&P 500, 52 weeks:-
Beta:0.28
Valuation Multiples
P/E (trailing):34.18
Diluted EPS for the last 12 months: the four quarters ended Sep 30, 2026, from the accounts filed with the SEC on Nov 3, 2026. The P/E is the price divided by that EPS.
P/E (forward):26.41
PEG Ratio:2.16
Price / Book:7.22
Price / Sales (TTM):10.69
EV / Revenue:10.67
EV / EBITDA:26.34
Dividends
Current yield:-
Annual Dividend Rate:-
Dividend Trailing:$0.00
Yield Trailing:0.00%
5-Year Avg Yield:-
Payout Ratio:0.00%
Last Ex-Dividend Date:-
Valuation Context
P/E vs sector (indicative)
Most Recent Quarter:-
Fiscal Year (Next):-
Loading historical OHLCV database...
Date
Open
High
Low
Close
Volume
Financial Statements TTM (Trailing 12 Months)
Income Statement
Total Revenue (TTM):12.59B
Gross Profit:6.92B
EBITDA:5.10B
Net Income (TTM):4.41B
Rev Growth (YoY):+12.50%
Earnings Growth (YoY):+8.00%
Quarterly earnings growth (YoY):+6.50%
Margins
Gross Margin:-
EBITDA Margin:-
Operating Margin:-
Net Margin:-
Per Share
EPS Trailing (TTM):$15.53
Diluted EPS for the last 12 months: the four quarters ended Sep 30, 2026, from the accounts filed with the SEC on Nov 3, 2026. The P/E is the price divided by that EPS.
EPS Forward (Est.):$20.09
Revenue Per Share:$49.51
Cash Per Share:-
Book Value:$73.49
Last Dividend:-
Ex-Dividend Date:-
Last Split:-
Balance Sheet & Liquidity
Total cash:7.85B
Total Debt:1.98B
Net Debt (Debt - Cash):−5.87B (net cash)
Debt / Equity:9.77%
Current Ratio:3.19
Quick Ratio:2.54
Cash Flows
Operating Cash Flow:4.29B
Free Cash Flow (FCF):2.63B
FCF Yield (FCF / Market Cap):-
Enterprise Value:134.33B
EV / Revenue:10.67
EV / EBITDA:26.34
Profitability
ROE (Return on Equity):23.54%
ROA (Return on Assets):11.93%
P/E (trailing):34.18
P/E (forward):26.41
Price / Book:7.22
PEG Ratio:2.16
52-Week Change:+31.18%
S&P 500 change, 52 weeks:+11.37%
Historical Evolution (Last 4 Years)
Income Statement
Balance Sheet
Cash Flow
EPS and Earnings Per Share
Key EPS Metrics
EPS Trailing (TTM):$15.53
Diluted EPS for the last 12 months: the four quarters ended Sep 30, 2026, from the accounts filed with the SEC on Nov 3, 2026. The P/E is the price divided by that EPS.
EPS Forward (Est.):$20.09
P/E (forward):26.41
PEG Ratio:2.16
Growth and Margins
Earnings Growth YoY:-
Quarterly Earnings Growth YoY:-
Rev Growth YoY:-
Net Margin:-
Gross Margin:-
EBITDA Margin:-
Per Share
Revenue Per Share:$49.51
Cash Per Share:-
Book Value:$73.49
Cash Flows (TTM)
Free Cash Flow:2.63B
Operating Cash Flow:4.29B
EBITDA:5.10B
Total Revenue (TTM):12.59B
Net Income (TTM):4.41B
Fiscal Year (Last):-
EPS Surprise History - Last 4 Quarters
Actual vs. Analyst Estimates · Green = beat expectations · Red = missed
Quarter
Period
Actual EPS
Estimated EPS
Difference
Surprise %
Currency
Ownership Structure
Ownership Distribution
% Insiders:-
% Institutional:-
% Inst. (of Float):-
No. of Institutions:-
Visual distribution
InsidersInstitutionalFree Float
Shares & Short Interest
Shares Outstanding:253,460,924
Float (free shares):252,682,799
Short interest (shares):4,263,331
Short % of float:-
Short Ratio (days to cover):3.66
Short interest, prior month:-
Short Interest Date:-
Governance Score (1=Best, 10=Worst)
Overall risk:-
Audit Risk:-
Board risk:-
Compensation Risk:-
Shareholder rights risk:-
Top Institutional Holders
Position Change: ▲ Increased · ▼ Reduced · = Unchanged
Organization
Report Date
% Shares
No. Shares
Value (USD)
Change %
Top Mutual Funds
Position Change: ▲ Increased ▼ Decreased = Unchanged
Fund
Report Date
% Shares
No. Shares
Value (USD)
Change %
Recent Insider Trades
Executive / Insider
Title
Date
Action
Shares
Options Chain
CALLS
Strike
Last
Bid
Ask
Vol.
O.I.
IV
PUTS
Strike
Last
Bid
Ask
Vol.
O.I.
IV
Sentiment Metrics
Put/Call Ratio (Volume):-
Put/Call Ratio (O.I.):-
Max Pain (estimated):-
Total O.I. Calls:-
Total O.I. Puts:-
Expected move
Average IV (Calls ATM):-
Average IV (Puts ATM):-
Days to Expiration:-
Expected move (±):-
Vertex Pharmaceuticals Incorporated (VRTX) SEC filings: 10-K, 10-Q and 8-K
Direct links to financial reports filed with the SEC.
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Executive VP & Chief Patient and External Affairs Officer
57
1.88M
Dr. Ourania Tatsis Ph.D.
Executive VP & Chief Product Affairs Officer
55
2.07M
Dr. Carmen Bozic M.D.
Executive VP of Global Medicines Development & Medical Affairs and Chief Medical Officer
62
2.27M
Ms. Kristen C. Ambrose CPA
Senior VP & Chief Accounting Officer
49
-
Dr. Mark Bunnage D.Phil
Executive VP & Chief Scientific Officer
56
-
You have seen the engine room
A free account saves your simulator portfolios, your personal portfolio and your Academy progress, synced across devices. And, if you switch it on, the email alert the same day an insider buys stock in their own company.
Vertex Pharmaceuticals Incorporated (VRTX) — Healthcare — Biotechnology. VRTX is in the S&P 500 today. Model factor scores and market data, recalculated every trading day.
So far in 2026, VRTX has returned +17.1% against +11.4% for the S&P 500 (SPY): total return, dividends included on both sides, from Dec 31, 2025 to Nov 3, 2026.
VRTX ranks 167 of 461 on today's multifactor score, and 21 of the 55 Healthcare companies that score. Its strongest factor is quality (Z 0.74, ranked 43 of 468); its weakest is value (Z -0.57, ranked 406 of 489). Each factor ranks only the companies with data for it, and the multifactor score only those with all four: that is why the totals differ.
Factor scores
The Z-Score is how many standard deviations the company sits from the index average: 0 is average, positive is better than average, negative is worse.
Frequently asked questions about Vertex Pharmaceuticals (VRTX)
When does Vertex Pharmaceuticals report earnings?
Vertex Pharmaceuticals has no announced date in the Nasdaq public calendar checked (Nov 3, 2026 to Dec 7, 2026). Of its last 12 earnings announcements: 12 after the close (SEC filings through Nov 2, 2026). VRTX earnings dates and times, quarter by quarter →
What is Vertex Pharmaceuticals's P/E ratio?
Vertex Pharmaceuticals's P/E (price over earnings per share for the last twelve months) is 34.2 at the Nov 3, 2026 close. That EPS is the 12-month diluted figure from the SEC, the four quarters ended Sep 30, 2026. The median of the 54 Healthcare companies with a P/E is 30.5, and the S&P 500's, 23.5: Vertex Pharmaceuticals is above its sector median. Healthcare stocks, company by company →
Where does Vertex Pharmaceuticals rank on Quant500?
In the Nov 3, 2026 multi-factor ranking, Vertex Pharmaceuticals ranks 167 of 461, and 21 of the 55 Healthcare companies that score. The ranking orders S&P 500 companies by the average of four factors (momentum, value, quality and growth) and is recalculated every trading day. It is a model output, not investment advice. The full ranking →How it is calculated →
Have Vertex Pharmaceuticals insiders bought or sold shares?
SEC Form 4 shows no open-market purchase of Vertex Pharmaceuticals shares from August 2025 through Nov 3, 2026. The latest sale was on Jul 2, 2026, by an officer, for $800k. In total, from August 2025 through Nov 3, 2026: 0 purchases and 60 sales by directors, officers and large shareholders. All VRTX insider trades →
What sector is Vertex Pharmaceuticals in, and which index?
Vertex Pharmaceuticals is classified in the Healthcare sector (industry: Biotechnology), per the data provider's classification (similar to GICS, not identical). It is in the S&P 500 today. It is one of the 59 S&P 500 companies in that sector. Healthcare stocks →
What is behind these numbers
The concepts on this page, explained from scratch in the Academy. Free, no account.
Quality and low volatilityWhere the quality score comes from, and why it is the factor with the most competing definitions, all of them called the same thing.
We save the portfolios you design, your own portfolio and your Academy progress, synced across devices.
Free, no card. Two automatic emails and no more: the one that confirms your address and the welcome one. After that, nothing you do not switch on yourself in your profile — such as the alert for insider buys, the same day they are reported to the SEC.